If you have started Wegovy, Ozempic or Mounjaro, there is a good chance you have noticed it in your stomach. Nausea after an injection, feeling full after just a few bites, or unpredictable visits to the bathroom — these are some of the most commonly reported experiences among people taking GLP-1 medications. But why does this happen, and what can you do about it?
The short answer is that GLP-1 receptors are found throughout the digestive tract — not just in the pancreas, where insulin regulation takes place. This means the medication actively changes how your gut works, which is part of why it is so effective at reducing appetite and causing weight loss. But it also means that digestive side effects are an expected and common part of the treatment.
Why does GLP-1 affect the gut?
GLP-1 (glucagon-like peptide-1) is a hormone your body produces naturally, primarily in the L-cells of the small intestine. In nature, it is released after a meal and sends signals to the brain that you are full, stimulates insulin secretion, and slows the movement of food through the digestive tract.
Medications like semaglutide (Wegovy, Ozempic) and tirzepatide (Mounjaro) mimic — or enhance — this hormone at far higher levels than the body would normally produce. GLP-1 receptors sit on cells throughout the digestive system: in the stomach, the small intestine, and even in the colon. When the medication activates these receptors, it slows the entire digestive process. This slowing is intentional — it is one of the mechanisms by which you feel full for longer — but it also brings side effects.
Nausea — the most common side effect
Nausea is the single most common side effect of GLP-1 medications. In the large STEP 1 clinical trial with semaglutide (Wegovy), approximately 44% of participants reported nausea at some point during treatment, compared to 16% in the placebo group. For tirzepatide (Mounjaro), the SURMOUNT-1 trial showed similar rates — around 30–45% depending on the dose.
The nausea typically occurs within the first few hours after injection and tends to be worst in the early weeks of treatment and after each dose increase. Most people find it significantly improves over the first 4–8 weeks as the body adapts.
Practical tips to reduce nausea:
- Eat smaller, more frequent meals rather than large portions
- Avoid high-fat, very spicy or very sweet foods right after injecting
- Inject at a time of day that works for you — some people prefer evenings so they sleep through the worst of it
- Stay hydrated, but sip water slowly rather than drinking large amounts at once
- If nausea is severe, ask your doctor — anti-nausea medication can be used short-term
Slowed gastric emptying — feeling full much faster
One of the key effects of GLP-1 medication on the gut is delayed gastric emptying — the stomach empties its contents into the small intestine more slowly than usual. This is a significant reason why people on these medications feel full after much smaller amounts of food.
Under normal circumstances, it takes the stomach roughly 2–4 hours to empty a mixed meal. On GLP-1 medication, this can be extended substantially. Radiological studies have confirmed measurably slower gastric emptying in patients taking semaglutide.
This is generally a desired effect. However, it can also cause:
- A feeling of fullness or bloating after even small meals
- Belching or regurgitation
- In rare cases, symptoms resembling gastroparesis (severe slowing of stomach emptying)
If you develop persistent vomiting, inability to keep food down, or significant bloating, contact your doctor. True gastroparesis is a rare but serious complication that has been reported in connection with GLP-1 treatment.
Constipation or diarrhea — why both can happen
GLP-1 medications can cause both constipation and diarrhea, often at different stages of treatment.
Constipation
Constipation is one of the most common long-term GI complaints. When the entire digestive tract slows down, it takes longer for waste to move through the colon, and more water is reabsorbed — making stools harder and more difficult to pass. In the STEP 1 trial, approximately 24% of Wegovy users reported constipation.
To prevent and manage constipation:
- Drink plenty of water (at least 1.5–2 litres per day)
- Increase dietary fibre (vegetables, legumes, whole grains)
- Stay physically active — even short walks help gut motility
- If needed, a gentle osmotic laxative (like macrogol/polyethylene glycol) is safe alongside GLP-1 treatment
Diarrhea
Diarrhea tends to occur more in the early weeks of treatment, particularly after a dose increase, as the gut adjusts. It typically resolves on its own. In some people, particularly with tirzepatide (Mounjaro), diarrhea can be quite pronounced initially. Staying hydrated and eating bland, low-fat foods during flare-ups helps considerably.
GLP-1 medication and the gut microbiome
One of the most exciting areas of current research is the effect of GLP-1 medications on the gut microbiome — the trillions of bacteria, viruses and fungi that live in the intestine. Early research suggests that GLP-1 treatment may beneficially shift the composition of gut bacteria.
A 2024 study published in Cell Metabolism found that semaglutide treatment was associated with increases in bacteria associated with short-chain fatty acid production — compounds that support gut barrier integrity and reduce inflammation. The researchers noted that some of the weight-loss effect of semaglutide may be mediated in part through changes in the microbiome.
This is an emerging field and much is still uncertain. However, it suggests that the gut effects of GLP-1 medication may extend beyond simple motility changes, potentially benefiting gut health in the longer term.
Vomiting — when should you worry?
Occasional vomiting, especially during the first few weeks of treatment or after a dose increase, is not unusual. However, you should contact your doctor if:
- Vomiting is persistent (more than 24 hours)
- You cannot keep food or fluids down
- You notice blood in your vomit
- You experience severe abdominal pain, especially in the upper abdomen or radiating to the back (this could indicate pancreatitis — a rare but serious complication)
It is also important to know that persistent vomiting while on GLP-1 medication may affect medication absorption, particularly for oral medications you may be taking for other conditions.
Practical tips for gut comfort on GLP-1 treatment
Most people find that gut side effects improve significantly over the first 2–3 months of treatment. In the meantime, these strategies help:
- Eat slowly and chew thoroughly — slower eating gives the digestive system more time to signal fullness and reduces the risk of overfilling a stomach that is already emptying slowly
- Avoid trigger foods — very fatty, fried, or heavily spiced foods are harder for a slow-moving gut to manage
- Eat at regular times — the gut thrives on routine, and regular meal times help stabilise digestive patterns
- Don't lie down right after eating — staying upright for 30–60 minutes after meals reduces reflux and belching
- Reduce alcohol and carbonated drinks — both can worsen bloating and nausea
- Be patient with dose increases — if a dose increase causes severe GI symptoms, speak to your doctor about slowing the titration schedule
What about long-term gut health?
For most people, the most uncomfortable GI side effects are temporary. As the body adapts to the medication, nausea, diarrhea and vomiting typically lessen significantly. Constipation may persist longer but can be managed effectively with dietary changes and hydration.
Importantly, there is no evidence that GLP-1 medications cause lasting damage to the gut lining or digestive organs in the vast majority of users. Ongoing research into the gut microbiome even suggests potential long-term benefits. The exception is the rare complication of gastroparesis, which can develop or worsen in susceptible individuals — another reason to discuss any persistent or worsening GI symptoms with your doctor.
Conclusion
GLP-1 medications are powerful because they engage with receptors throughout the gut — and that engagement comes with digestive side effects that are real but manageable. Nausea, constipation, diarrhea and fullness are expected parts of the treatment journey, especially early on. With the right strategies, most people adapt well and the side effects diminish over time.
Always talk to your doctor before making changes to your medication or if you are concerned about persistent digestive symptoms during your treatment.
Sources
- STEP 1 Trial — Semaglutide 2.4 mg for Weight Reduction (NEJM, 2021)
- SURMOUNT-1 Trial — Tirzepatide for Obesity (NEJM, 2022)
- Wegovy (semaglutide) — European Medicines Agency product information
- GLP-1 receptor agonists and the gut microbiome — PMC (2024)
- Gastrointestinal effects of GLP-1 receptor agonists — PMC (2023)
- Gastroparesis and GLP-1 receptor agonists — a review (PubMed, 2024)